1. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., and Jones, J. M. (1998) Embryonic stem cell lines derived from human blastocysts, Science
282, 1145–1147.
2. Crook, J. M., Peura, T. T., Kravets, L., Bosman, A. G., Buzzard, J. J., Horne, R., Hentze, H., Dunn, N. R., Zweigerdt, R., Chua, F., Upshall, A., and Colman, A. (2007) The generation of six clinical-grade human embryonic stem cell lines, Cell Stem Cell
1, 490–4.
3. Carpenter, M. K., Frey-Vasconcells, J., and Rao, M. S. (2009) Developing safe therapies from human pluripotent stem cells, Nat Biotechnol
27, 606–613.
4. FDA, Guidance for Industry (2009) Current good tissue practice (CGTP) and additional requirements for manufacturers of human cells, tissues, and cellular and tissue-based products (HCT/Ps).
5. FDA, Guidance for FDA reviewers and sponsors (2008) Content and review of chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs).